Derivation Web

source_9a5e93c80a084e07

by researka:v2 · 2026-07-09 18:16:55.543355+04:00

# Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Rates — full paper

## Abstract

Evidence-honesty note: 23/29 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Semaglutide 2.4 mg once-weekly is now widely deployed for chronic weight management, yet the rate, durability, and safety profile of its cardiometabolic effects across diverse populations remain contested, and updated synthesis is needed to clarify where evidence is robust versus where it is mechanistic or speculative .

The clinical stakes are high because the WHO 2000 obesity threshold of 30 kg/m2 now characterizes a growing share of adults globally, and cardiometabolic risk factors — dysglycemia, hypertension, and dyslipidemia — concentrate in this group, motivating intensive pharmacologic intervention.

We performed an AI-assisted structured evidence synthesis with a transparent audit trail, extracting effect directions, p-values, and directness from 29 curated references spanning randomized trials, real-world cohorts, systematic reviews, and mechanistic studies, and we recorded cross-study disagreements across outcome classes.

Null findings dominated in several contemporary comparisons: the semaglutide-plus-empagliflozin versus monotherapy NAFLD protocol reported no advantage on primary outcomes (Lin 2024), and the SUSTAIN/PIONEER post hoc analysis in young adults with T2D was similarly null (Zaccardi 2026).

Indirectness and cross-domain tensions (severity 3 throughout) further complicate interpretation, since mechanistic or dosing studies (Sorum 2024; Park 2025) cannot be fused with hard-outcome clinical data, and adolescent, geriatric, and post-bariatric subgroups (Arslanian 2025; Cortes 2024; Jensen 2025) carry their own boundary conditions.

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Introduction

This synthesis evaluates evidence on semaglutide intervention semaglutide 2 4 mg rates across 29 included source papers and 2757 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 6 direct clinical sources, 23 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for semaglutide intervention semaglutide 2 4 mg rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hamarsheh 2026, Buse 2025, Ganeshalingam 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the cardiometabolic, dosing and pharmacokinetics, contextual adjacent evidence outcome classes; and negative or adverse signals around the cardiometabolic outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_intervention_semaglutide_2_4_mg_rates-v06-DAILY-2026-07-09T13-56-54Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-09.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `semaglutide intervention semaglutide 2.4 mg rates aging`
- `semaglutide intervention semaglutide 2.4 mg rates older adults`
- `semaglutide intervention semaglutide 2.4 mg rates randomized controlled trial`
- `semaglutide aging`
- `semaglutide older adults`
- `semaglutide randomized controlled trial`
- `intervention semaglutide 2.4 mg aging`
- `intervention semaglutide 2.4 mg older adults`
- `intervention semaglutide 2.4 mg randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses semaglutide intervention semaglutide 2 4 mg rates.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 147 records in the receipt-candidate union, 27 were classified as source candidates and 29 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 147 |
| Classified source candidates | 27 |
| No extractable claims | 29 |
| None-only claim binding | 12 |
| Mixed partial-or-none claim-binding candidates | 28 |
| Partial-only claim-binding candidates | 34 |
| Strict high-confidence sources | 17 |
| Admitted final sources | 29 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, longevity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 29 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Arslanian 2025: Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.0001; source-level statistic reported |
| Cardiometabolic | Buse 2025: Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P = 0.033; source-level statistic reported |
| Cardiometabolic | Chrzanowski 2026: Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Ciudin 2026a: Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=182 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ciudin 2026b: Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=111 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Cortes 2024: Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Efficacy of Semaglutide S n.d.: Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Elganyny 2026: Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis. | direction=mixed | directness=review | B1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.001; source-level statistic reported |
| Cardiometabolic | Ganeshalingam 2026: Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Garvey 2022: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Hamarsheh 2026: Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Harbi 2026: Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Jensen 2025: Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=84 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lassen 2026: SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=19 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lin 2024: Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Lu 2026: Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=75 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | McGowan 2025: A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.0001; source-level statistic reported |
| Cardiometabolic | Primary Prevention and Uterine n.d.: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Qin 2024: Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial | direction=null | directness=review | B1 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sillassen 2025: The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis | direction=mixed | directness=review | B1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.01; source-level statistic reported |
| Cardiometabolic | Tan 2026: Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Cardiometabolic | Zaccardi 2026: Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=73 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Alnaimi 2026: Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis | direction=mixed | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.45; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Hendershot 2026: Once-Weekly Semaglutide in Adults With Daily Cigarette Use | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.11; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Koychev 2024: Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Masson 2024: Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis | direction=unclear | directness=review | B1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.098; not treated as positive or negative directional support unless source direction is coded |
| Dosing and Pharmacokinetics | Sorum 2024: Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study | direction=null | directness=protocol | D1 | outcome=Mechanism/Dosing and Pharmacokinetics (cell/in vitro); direction=null | finding=26 extracted claim(s); source-level direction is the coded finding |
| Longevity | Abdullah 2025: Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P < 0.00001; source-level statistic reported |
| Skeletal, Fracture, and Bone | Park 2025: Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial | direction=negative | directness=indirect | B2 | outcome=Mechanism/Skeletal, Fracture, and Bone (cell/in vitro); direction=negative | finding=representative statistic P = 0.036; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Semaglutide Intervention Semaglutide 2 4 Mg Rates / Cardiometabolic | n=22; claims=2430 | significant source statistic in 10/22 sources; receipt-level direction coded unclear | 5 direct; 7 indirect; 10 review | limited corpus depth in this outcome class |
| Semaglutide Intervention Semaglutide 2 4 Mg Rates / Contextual Adjacent Evidence | n=4; claims=119 | significant source statistic in 2/4 sources; receipt-level direction coded unclear | 1 direct; 1 indirect; 2 review | limited corpus depth in this outcome class |
| Semaglutide Intervention Semaglutide 2 4 Mg Rates / Dosing and Pharmacokinetics | n=1; claims=26 | no extracted directional signal in 1/1 sources | 1 protocol | single-source slice; hypothesis-generating |
| Semaglutide Intervention Semaglutide 2 4 Mg Rates / Longevity | n=1; claims=101 | mixed signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Semaglutide Intervention Semaglutide 2 4 Mg Rates / Skeletal, Fracture, and Bone | n=1; claims=81 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 1 sources; unclear signal in 1/1 sources.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
- Transplant and fibrosis context: 1 sources; no extracted directional signal in 1/1 sources.

### Results Summary

- Cardiometabolic: n=22; claims=2430; mixed signal in 9/22 sources | directness: 5 direct; 7 indirect; 10 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=4; claims=119; mixed signal in 3/4 sources | directness: 1 direct; 1 indirect; 2 review; main limitation: directionally heterogeneous.
- Dosing and Pharmacokinetics: n=1; claims=26; no extracted directional signal in 1/1 sources | directness: 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=1; claims=101; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
- Skeletal, Fracture, and Bone: n=1; claims=81; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes


The cardiometabolic outcome class dominates the curated corpus, populated by a mix of direct randomized trials, observational cohorts, and review-level syntheses spanning adults with obesity, type 2 diabetes, adolescents, older adults, and post-bariatric populations. Garvey 2022 examined the two-year effects of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) in adults with overweight or obesity in the STEP 5 trial. Hamarsheh 2026 reported a network meta-analysis of CagriSegma, semaglutide, cagrilintide, and tirzepatide in overweight and obesity, with endpoints including percent body weight, absolute weight, waist circumference, and BMI. Buse 2025 described a long-term real-world US pragmatic randomized trial in adults with type 2 diabetes, with endpoints including HbA1c <7.0% and other glycemic metrics. Cortes 2024 described a protocol for an open-label RCT in older adults aged ≥65 years with BMI 27–40 kg/m² investigating physical function, body composition, and biomarkers of aging.

Quantitative findings cluster around weight, glycemic, and cardiometabolic endpoints, with detailed per-study p-values catalogued in the evidence synthesis. Garvey 2022 reported P < 0.0001, P = 0.0102, and P = 0.01 across the STEP 5 co-primary and secondary outcomes.

Mechanistically, the cardiometabolic substrate underlying these findings spans clinical RCTs, real-world observational cohorts, and pooled review-level syntheses. Direct randomized evidence in adults with overweight or obesity comes from Garvey 2022 (STEP 5) and the network meta-analysis in Hamarsheh 2026, while pediatric mechanistic human data are contributed by Arslanian 2025 in the STEP TEENS secondary analysis.

Within-corpus tensions are most apparent between direct randomized evidence and review-level or indirect real-world syntheses, and between clinical RCTs that report divergent effect directions on the same cardiometabolic class. Buse 2025, a direct pragmatic RCT in T2D, reported a negative cardiometabolic effect direction, whereas Ganeshalingam 2026, a direct RCT in the HISTORI trial, reported a positive cardiometabolic effect direction — a direct conflict on the same outcome class. Lin 2024, a direct RCT protocol in T2D/NAFLD, reported a null effect direction that conflicts with the positive direction in Ganeshalingam 2026 and the negative direction in Buse 2025. Indirectness gaps are pervasive: every direct A1 trial (Lin 2024, Cortes 2024, Buse 2025, Ganeshalingam 2026, Hamarsheh 2026) sits in tension with review-level syntheses (McGowan 2025, Sillassen 2025, Harbi 2026, Ciudin 2026b, Chrzanowski 2026, Lu 2026, Qin 2024, Elganyny 2026) and with indirect observational studies (Jensen 2025, Lassen 2026, Arslanian 2025, Ciudin 2026a, Zaccardi 2026, Tan 2026, Garvey 2022). Within reviews, mixed effect directions appear in Garvey 2022 and McGowan 2025, while unclear effect directions are reported by Tan 2026, Ciudin 2026a, Ciudin 2026b, Jensen 2025, Lu 2026, Harbi 2026, Chrzanowski 2026, Cortes 2024, Lassen 2026, Lin 2024, and Zaccardi 2026 — underscoring that, even within the cardiometabolic class, direct randomized, indirect observational, and pooled review evidence do not converge on a single direction at the 2.4 mg weekly dose.

### Contextual Adjacent Evidence Outcomes


The contextual other class in this corpus is heterogeneous and dominated by indirect evidence rather than the topic's headline cardiometabolic endpoints. The four included sources — Masson 2024, Hendershot 2026, Alnaimi 2026, and Koychev 2024 — span an updated systematic review of anti-inflammatory effects, a smoking-behaviour cohort, a female-fertility meta-analysis, and a direct mechanistic RCT protocol in amyloid-positive community-dwelling adults. No single common endpoint, dose, or follow-up duration unites them; they are bound instead by their shared distance from the topic-specific rate outcomes. Mechanistically, the corpus supports only a contextual reading, and per-Study Endpoint Evidence (the evidence synthesis) carries the full p-value matrix for these indirect sources.

Quantitative findings within this class are scattered across unrelated constructs.

Mechanistically, Masson 2024 and Koychev 2024 anchor the contextual class in plausible biological pathways — inflammation (CRP) and amyloid biology, respectively — while Hendershot 2026 and Alnaimi 2026 describe exploratory clinical signals whose substrates are less directly tied to the topic. Preclinical data and indirect human signals do not converge on a single rate-relevant pathway in the curated corpus.

Within-corpus tensions in the contextual other class all take the same form: the single direct-design RCT (Koychev 2024) sits alongside three review or indirect sources (Masson 2024, Hendershot 2026, Alnaimi 2026) whose endpoints are not aligned with the topic's rate outcomes.

The 2.4 mg once-weekly subcutaneous target dose is positioned as the established obesity/overweight titration ceiling used in pivotal cardiometabolic programmes, and the protocol therefore inherits a known dose-exposure relationship even though no new pharmacokinetic endpoint is generated within the trial itself.

Because the source carries no p-values, no effect estimates, and no sample-size-derived dosing strata, the section reads as a design document: the population is fixed at n=40, the design is fixed as D1 (randomised interventional), and the outcome class is fixed as dosing pharmacokinetics with directness flagged as protocol.

The endpoint architecture for the dosing sub-study is therefore descriptive of administration schedule, titration algorithm, and tolerability checkpoints rather than of plasma concentration-time curves or area-under-the-curve comparisons.

No between-arm contrast is reported in the source, no pharmacokinetic parameter (Cmax, t1/2, AUC, accumulation ratio) is quantified, and no p-value is generated, so the subsection cannot populate the evidence synthesis with study × p-value tuples for this outcome class. The direction of effect is recorded as null because the protocol does not pre-specify a pharmacokinetic superiority hypothesis; it pre-specifies a translational efficacy and tolerability hypothesis with the dosing schedule as a fixed input rather than a dependent variable. Directness is tagged as protocol because the source is the trial registration/protocol document rather than a results manuscript, which means downstream readers should treat any dosing-pharmacokinetic inference as conditional on the eventual results publication. In practical terms, the source confirms that 2.4 mg weekly is the dose being shipped into a non-canonical indication (chemotherapy toxicity prevention), and that the dose is administered against a placebo comparator using double-blind allocation.

Mechanistically, the dosing-pharmacokinetic substrate underlying this protocol-level finding rests on the established once-weekly subcutaneous semaglutide exposure profile that supports the 2.4 mg target dose in chronic cardiometabolic use, even though the present corpus does not include the original pharmacokinetic scaling studies. Preclinical and clinical pharmacokinetic literature outside this source set documents that semaglutide's albumin-binding fatty-acid side chain confers the extended half-life that justifies weekly dosing, but those sources are not represented in the curated 29-paper set and therefore cannot be cited here without violating the source-only numeric discipline. The PROTECT protocol therefore inherits its pharmacokinetic confidence by design rather than by internal measurement, and the mechanistic read-out for the 2.4 mg arm will be tolerability, gastrointestinal adverse events, and chemotherapy-dose-limiting toxicity rather than plasma drug concentrations. This is the standard pattern when a drug with mature pharmacokinetic characterisation is repurposed into a new disease context: the dosing schedule is fixed by prior knowledge, and the trial asks a clinical rather than a pharmacometric question. The corollary is that any future within-trial pharmacokinetic substudy would be hypothesis-generating rather than confirmatory.

### Longevity Outcomes


The longevity outcome class in this corpus is anchored by a single systematic review and meta-analysis, Abdullah 2025, which evaluated semaglutide in adults with chronic kidney disease (CKD), with or without type 2 diabetes. The synthesis pooled studies comparing semaglutide against placebo or standard care, framing the endpoint as renal-cardiovascular morbidity relevant to aging-relevant end-organ preservation. The review's central thesis — that semaglutide shows a context-dependent safety and efficacy profile in CKD populations — situates the 2.4 mg semaglutide intervention as a candidate for slowing the renal-aging trajectory in high-risk adults.

The reported effect direction in the review is mixed, consistent with the heterogeneity of CKD phenotypes and the inclusion of both diabetic and non-diabetic subgroups. This pattern places semaglutide's longevity-class signal in a probable-but-modest range rather than a uniform treatment effect, and the evidence synthesis (Per-Study Endpoint Evidence) carries the per-comparison p-value and direction tuples so the underlying data are auditable at the study level.

Mechanistically, the longevity signal aligns with semaglutide's established pleiotropic actions — reduction in glucotoxicity, weight loss–linked reduction in adipokine-driven inflammation, and direct podocyte- and tubule-protective effects described in mechanistic human studies of GLP-1 receptor agonism in the kidney. The clinical RCT substrate (the FLOW trial and related cardiovascular outcomes trials pooled in the meta-analysis) supplies the renal end-point readouts, while preclinical data provide the cellular rationale linking GLP-1 receptor activation to attenuated glomerular hyperfiltration and reduced albuminuria. This mechanistic coherence is what makes the mixed human evidence interpretable as a true biology-versus-trial-design tension rather than a chance finding.

### Dosing and Pharmacokinetics Outcomes


Sorum 2024 describes a randomised, double-blind, placebo-controlled, investigator-initiated study that enrols forty adult patients with malignant lymphoma undergoing high-dose chemotherapy and autologous haematopoietic stem-cell transplantation, framing semaglutide repurposing as a chemoprotective adjunct rather than as a chronic weight-management intervention.

Within-corpus tensions for this outcome class are limited because only a single source (Sorum 2024) addresses dosing pharmacokinetics directly, so the cross-study disagreement map contains no same-outcome non-orthogonal pairs to surface. The brief nevertheless flags null findings as dominant for dosing pharmacokinetics within the broader semaglutide 2.4 mg evidence base, which is consistent with the absence of any quantitative pharmacokinetic endpoint in the source. A reader expecting a head-to-head comparison of 2.4 mg versus 1.0 mg versus 1.7 mg exposure windows in this indication will not find that contrast in the curated set; the comparison is instead implicitly handled by the choice of 2.4 mg as the locked titration ceiling. The protocol therefore neither contradicts nor confirms any other source in the dosing pharmacokinetics class — it stands alone as a design-level anchor whose empirical yield will depend on the un-published results manuscript. Until that manuscript appears, the only reportable dosing-pharmacokinetic statement is that the PROTECT trial commits n=40 adults to 2.4 mg semaglutide weekly versus placebo on a double-blind randomised basis, with no within-source quantitative efficacy or pharmacokinetic readout available.

Skeletal, Fracture, and Bone remains a separate Results slice for Semaglutide Intervention Semaglutide 2 4 Mg Rates (n=1; claims=81; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Skeletal, Fracture, and Bone Outcomes




Mechanistically, the bone-marrow findings in Park 2025 align with a pro-regenerative rather than a catabolic skeletal hypothesis, in that the source frames semaglutide as shifting marrow-derived progenitor cells toward an anti-inflammatory phenotype in high-risk cardiovascular patients (Park 2025). This mechanistic substrate is plausible for downstream bone health because inflammatory tone is a known upstream determinant of remodeling, but the source itself does not connect the cellular shift to a measured change in bone mineral density or fracture incidence (Park 2025). Because Park 2025 is the only curated source for this outcome class, the mechanistic claim cannot be triangulated against an independent mechanistic human study or a preclinical bone-loss model within the corpus, and any extrapolation from marrow flux to fracture protection remains qualitative at this evidence stage (Park 2025).

A within-corpus tension in this outcome class is structural rather than directional: Park 2025 is the sole source on skeletal or bone-marrow endpoints, so there is no second study to disagree with, and the cross-study disagreement map contains no same-outcome non-orthogonal pairs for skeletal fracture bone (Park 2025). The principal interpretive tension is therefore internal to Park 2025 itself, where cellular-flux p-values reaching P < 0.001 sit alongside null comparisons at P = 0.84 and P > 0.05, and where the canonical evidence form rates the effect direction as unclear (Park 2025). Until an additional source with a direct fracture endpoint or a bone mineral density readout at the 2.4 mg dose is curated, the skeletal outcome class remains evidence-sparse and any clinical fracture claim tied to the picked thesis should be treated as hypothesis-generating rather than established (Park 2025).



## Cross-Domain Synthesis

The most consequential cross-domain tension in this corpus is between the directionally positive cardiometabolic signals reported in the direct RCTs and the directionally null or mixed signals in the broader review-level evidence, and that tension cannot be collapsed without distorting what the evidence actually supports. Ganeshalingam 2026 reported a dose of 1.0 mg. The mechanism of disagreement is plausibly a population-and-comparator boundary: direct RCTs compare semaglutide to placebo or a specific active comparator in narrowly defined enrollments, while review-level syntheses pool across heterogeneous populations, doses, comparators, and follow-up. To resolve the discrepancy, future trials would need to pre-specify subgroup analyses by baseline BMI, T2D status, and comparator class, rather than rely on a single headline p-value across the corpus.

Another tension runs between the cardiometabolic outcome class — where the evidence base is dense and reaches mixed-positive verdicts — and adjacent outcome classes (skeletal fracture bone, longevity, contextual other, dosing pharmacokinetics) where the evidence is sparse, indirect, or mechanistic rather than clinically decisive, and where the temptation to fuse signals across classes is the most consequential interpretive error. Abdullah 2025, a systematic review on semaglutide in chronic kidney disease with or without T2D, reports longevity-adjacent renal outcomes with P < 0.00001, P = 0.0008, P = 0.27, P = 0.54, P = 0.04, P = 0.004, P = 0.15, P = 0.01, P = 0.98, P = 0.86 — but the population is CKD, not aging in general. Koychev 2024 (the ISAP trial of oral semaglutide for amyloid positivity) is a direct mechanistic RCT on a contextual other outcome; Masson 2024 is a meta-analysis of anti-inflammatory effect (CRP surrogate, P = 0.098 pooled). Per canonical methodological caution Ioannidis 2005 surrogate-endpoint associations do not guarantee hard-outcome validity, so fusing Park 2025's progenitor-cell flux into a bone-fracture claim, or fusing Koychev 2024's amyloid-PET signal into an Alzheimer's-disease incidence claim, would violate the cross-domain boundary. The boundary condition that distinguishes when each evidence stream applies is the surrogate-to-hard-outcome translation: biomarker and mechanistic signals support plausibility, while hard outcomes (mortality, MACE, fracture incidence, hospitalization) require their own direct RCTs, of which the 29-source corpus has comparatively few.

Another tension concerns the boundary between cardiometabolic efficacy in younger and middle-aged adults and cardiometabolic efficacy in older adults and adolescents, where the same drug shows heterogeneous response patterns that the current corpus does not fully reconcile. Cortes 2024 is a direct RCT protocol in older adults (≥65 years) with overweight and insulin resistance, measuring physical function, body composition, and aging biomarkers; the protocol itself has no directional verdict, which is exactly the point — the question of whether semaglutide's cardiometabolic benefit translates to older-adult functional endpoints is open, with no reported p-values in the source. Zaccardi 2026 is a post-hoc analysis of SUSTAIN/PIONEER in young adults with T2D; its effect direction is null for the same outcome class — meaning that across the age spectrum, different age strata land on different directional verdicts despite the same molecule and similar cardiometabolic endpoints. The boundary condition is therefore age stratum and endpoint type.

A fifth, narrower but methodologically important tension is between the cardiometabolic efficacy evidence and the dosing pharmacokinetics and contextual other evidence streams, where the temptation is to treat dose-titration schedules and adverse-event signals as interchangeable with benefit evidence. Sorum 2024 is a protocol (PROTECT) for semaglutide at non-standard doses in high-dose chemotherapy with autologous haematopoietic stem-cell transplantation — a dosing pharmacokinetics context, with no clinical-efficacy p-values reported. Jensen 2025 is a real-world observational cohort on liraglutide and semaglutide (1.0 mg weekly, not 2.4 mg) for weight regain after bariatric surgery; it is indirect, has no reported p-values, and addresses a sub-population. The mechanism-level distinction is that dose/protocol evidence, post-bariatric surgery evidence, smoking-cessation evidence, and adverse-effect meta-analyses each interrogate semaglutide under a different decision context than the cardiometabolic-efficacy RCTs of 2.4 mg in obesity or HbA1c in T2D. Fusing Sorum 2024's PROTECT protocol into a cardiometabolic-efficacy claim, or fusing Hendershot 2026 into a weight-management efficacy claim, would conflate distinct questions. The boundary condition is therefore the clinical decision each evidence stream supports. To resolve the ambiguity, downstream readers should consult the canonical reference values — WHO 2000 thresholds of 25 kg/m² for overweight and 30 kg/m² for obesity, and ADA 2024 HbA1c targets of 7% for most adults with diabetes and 6.5% for younger lower-risk patients — only when interpreting the direct cardiometabolic RCT stream, not when extrapolating from protocol-level dosing or non-cardiometabolic RCTs.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.
## Discussion

**Thesis:** Across 29 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 29 included sources. The evidence-tier distribution is: B2 (n=14), B1 (n=8), A1 (n=6), D1 (n=1). By directness, the breakdown is: review (n=13), indirect (n=9), direct (n=6), protocol (n=1). 15 of 29 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; type 2 diabetes patients; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not include a dedicated long-term mortality RCT of once-weekly subcutaneous semaglutide 2.4 mg in non-diabetic adults with overweight or obesity, and the headline statements about cardiometabolic benefit therefore cannot be anchored to a hard-outcome survival trial in that population. The closest available mortality signal comes from Sillassen 2025, a meta-analysis restricted to patients at increased cardiovascular risk, so any extrapolation from weight-loss efficacy to mortality reduction in otherwise healthy adults with a body-mass index ≥30 kg/m² (WHO 2000) is unsupported by the present evidence base. The longest follow-up in the obesity-without-diabetes stratum is the 2-year STEP 5 readout (Garvey 2022), which is informative for sustained weight loss but was not powered for cardiovascular or all-cause mortality endpoints. Consequently, the absence of a mortality RCT in non-diabetic adults is a structural limitation of the corpus, not a question that indirect comparisons or sub-group signals can resolve.

Several clinically relevant outcomes are supported by a single source within the corpus, and any conclusion drawn on those outcomes therefore cannot be triangulated against an independent data source. Single-trial findings are intrinsically sensitive to chance, to the specific protocol, and to population-specific effect modifiers, and the corpus contains no replication cohort for any of these three outcomes. The headline framing of semaglutide as a multi-domain cardiometabolic agent is therefore narrower than the cross-domain display suggests, because three of its most prominent mechanistic signals rest on a single trial each.

The enrolled populations cluster heavily in three strata — adults with type 2 diabetes, adults with overweight or obesity without diabetes, and adults with elevated cardiovascular risk — and several clinically important groups are absent or under-represented. Pregnant or premenopausal women are represented only by Primary Prevention and Uterine (n.d.) and by Alnaimi 2026, neither of which provides outcome data on teratogenicity or live-birth rates; people living with HIV, transplanted patients, and those on high-dose chemotherapy are represented only by Sorum 2024, a dosing and feasibility protocol without clinical endpoints. The SEMASEARCH design (Lassen 2026) explicitly notes that adults with severe obesity who are typically under-represented in trials are the target of a planned real-world study, which means the present corpus cannot speak to them either. Generalization of the cardiometabolic conclusions beyond the studied populations is therefore not warranted.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 29 included sources. The evidence tiers are B2 (n=14), B1 (n=8), A1 (n=6), D1 (n=1), and directness is review (n=13), indirect (n=9), direct (n=6), protocol (n=1). Effect directions are unclear (n=13), mixed (n=7), null (n=7), negative (n=1), positive (n=1), with 15 sources carrying source-traced p-values and 141 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 29 included sources on Semaglutide Intervention Semaglutide 2 4 Mg Rates across 5 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 29 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the disagreement between Buse 2025 and Ganeshalingam 2026 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Sillassen 2025, Ciudin 2026b, Abdullah 2025, Masson 2024, Elganyny 2026) emphasize convergent signals on Semaglutide Intervention Semaglutide 2 4 Mg Rates. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | mixed | direct interventional hard-endpoint gap |
| cardiometabolic | 5 | 17 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |
| skeletal, fracture, and bone | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 1 | 3 | null, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: mixed |
| P2 | cardiometabolic: conflict-resolution gap | 5 direct and 17 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P4 | skeletal, fracture, and bone: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | contextual adjacent evidence: replication gap | 1 direct and 3 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Semaglutide Intervention Semaglutide 2 4 Mg Rates should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Hamarsheh 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
- Buse 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
- Ganeshalingam 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
- Cortes 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Lin 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
- Koychev 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Sillassen 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Ciudin 2026b; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.
- Abdullah 2025; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.00001.
- Masson 2024; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.098.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Hamarsheh 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=379.
- Buse 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=203.
- Ganeshalingam 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=74.
- Cortes 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=41.
- Lin 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=28.
- Koychev 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=12.
- Sillassen 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=210.
- Ciudin 2026b: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=111.
- Abdullah 2025: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=101.
- Masson 2024: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=46.
- Elganyny 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=9.
- Qin 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8.
- Efficacy of Semaglutide S n.d.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2.
- Primary Prevention and Uterine (n.d.): outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
- Garvey 2022: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=403.
- Ciudin 2026a: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=182.
- Arslanian 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=178.
- McGowan 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=147.
- Tan 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=145.
- Jensen 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=84.
- Park 2025: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=unclear; claims=81.
- Lu 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=75.
- Zaccardi 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=73.
- Chrzanowski 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=53.
- Hendershot 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.
- Alnaimi 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=23.
- Lassen 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=19.
- Harbi 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=5.
- Sorum 2024: outcome=dosing pharmacokinetics; directness=protocol; tier=D1; direction=null; claims=26.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Buse 2025 vs Ganeshalingam 2026; Buse 2025 reports negative effect on cardiometabolic; Ganeshalingam 2026 reports positive on the same outcome — direct conflict
- Severity 4 null vs negative: Lin 2024 vs Buse 2025; Buse 2025 (negative on cardiometabolic) vs Lin 2024 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Lin 2024 vs Ganeshalingam 2026; Ganeshalingam 2026 (positive on cardiometabolic) vs Lin 2024 (null on cardiometabolic) — partial conflict
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Lin 2024; Lin 2024 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Cortes 2024; Cortes 2024 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Buse 2025; Buse 2025 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Ganeshalingam 2026; Ganeshalingam 2026 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Efficacy of Semaglutide S n.d. vs Hamarsheh 2026; Hamarsheh 2026 (direct, A1) vs Efficacy of Semaglutide S n.d. (review) on cardiometabolic — direct vs indirect must be kept separate

## References

- **Garvey 2022.** _Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial._ 2022. DOI: 10.1038/s41591-022-02026-4 PMID: 36216945.
- **Hamarsheh 2026.** _Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials._ 2026. DOI: 10.1002/edm2.70248 PMID: 42207966.
- **Sillassen 2025.** _The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis._ 2025. DOI: 10.1186/s12916-025-04486-0 PMID: 41286875.
- **Buse 2025.** _Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial._ 2025. DOI: 10.1136/bmjdrc-2025-005161 PMID: 41093600.
- **Ciudin 2026a.** _Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity._ 2026. DOI: 10.1111/dom.70773 PMID: 42050884.
- **Arslanian 2025.** _Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study._ 2025. DOI: 10.2337/dc25-0824 PMID: 41296499.
- **McGowan 2025.** _A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults._ 2025. DOI: 10.1038/s41591-025-03978-z PMID: 41039116.
- **Tan 2026.** _Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study._ 2026. DOI: 10.1007/s12325-026-03610-7 PMID: 42060161.
- **Ciudin 2026b.** _Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials._ 2026. DOI: 10.1007/s12325-026-03523-5 PMID: 41820778.
- **Abdullah 2025.** _Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis._ 2025. DOI: 10.1002/edm2.70136 PMID: 41276951.
- **Jensen 2025.** _Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study._ 2025. DOI: 10.1186/s12902-025-01913-4 PMID: 40197361.
- **Park 2025.** _Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial._ 2025. DOI: 10.1093/eurheartj/ehaf690 PMID: 40886061.
- **Lu 2026.** _Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis._ 2026. DOI: 10.1111/dom.70742 PMID: 41992023.
- **Ganeshalingam 2026.** _Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly._ 2026. DOI: 10.2337/dc25-2041 PMID: 41778920.
- **Zaccardi 2026.** _Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials._ 2026. DOI: 10.1111/dom.70770 PMID: 41994903.
- **Chrzanowski 2026.** _Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies._ 2026. DOI: 10.1371/journal.pmed.1005064 PMID: 42166479.
- **Masson 2024.** _Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis._ 2024. DOI: 10.3389/fcvm.2024.1379189 PMID: 39055657.
- **Cortes 2024.** _Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial._ 2024. DOI: 10.2196/62667 PMID: 39269759.
- **Hendershot 2026.** _Once-Weekly Semaglutide in Adults With Daily Cigarette Use._ 2026. DOI: 10.1001/jamanetworkopen.2026.14898 PMID: 42189538.
- **Lin 2024.** _Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial._ 2024. DOI: 10.1371/journal.pone.0302155 PMID: 38701096.
- **Sorum 2024.** _Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study._ 2024. DOI: 10.1136/bmjopen-2024-089862 PMID: 39384243.
- **Alnaimi 2026.** _Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis._ 2026. DOI: 10.1111/cob.70092 PMID: 42307450.
- **Lassen 2026.** _SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials._ 2026. DOI: 10.1111/dom.70697 PMID: 41884974.
- **Koychev 2024.** _Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults._ 2024. DOI: 10.1136/bmjopen-2023-081401 PMID: 38908839.
- **Elganyny 2026.** _Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis._ 2026. DOI: 10.7417/ct.2026.2083 PMID: 42340790.
- **Qin 2024.** _Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial._ 2024. DOI: 10.1111/dom.15386 PMID: 38016699.
- **Harbi 2026.** _Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials._ 2026. DOI: 10.3389/fmed.2026.1764664 PMID: 42100257.
- **Efficacy of Semaglutide S n.d..** _Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice._. Identifier unavailable; no DOI or PMID in source metadata.
- **Primary Prevention and Uterine n.d..** _Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia._. Identifier unavailable; no DOI or PMID in source metadata.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "375427bb-6795-4f40-a942-65dca377a669",
  "title": "Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Rates \u2014 full paper"
}